初次肺SBRT后孤立局部复发再程SBRT挽救的安全性与疗效
本研究基于前瞻性登记数据,纳入2008至2017年21例早期NSCLC初次SBRT后孤立局部复发并接受再程SBRT的患者,两程均为3-5次、BED10≥100 Gy。再程SBRT后中位总生存39个月,2年原发肿瘤控制81%、区域淋巴结控制89%、远地控制75%、总生存68%,仅见2级肺炎和2级胸壁毒性,无3级及以上毒性。
要点
- 再程SBRT后2年原发肿瘤控制81%、总生存68%。
- 仅2例2级肺炎、4例2级胸壁毒性,无3级及以上毒性。
- 再程SBRT后中位总生存为39个月。
核心结论
- 初次肺SBRT后孤立局部失败行再程SBRT看似安全,治疗相关毒性低且肿瘤控制率令人鼓舞。
研究设计与样本
- 利用前瞻性登记数据库识别2008至2017年接受再程SBRT的早期NSCLC孤立局部复发患者,共21例。
- 两程SBRT均为3-5次、BED10≥100 Gy,局部失败定义为距初始PTV 1 cm内或两次治疗≥25%等剂量线重叠。
- 采用Kaplan-Meier法估计生存。
主要发现
- 初次SBRT至再程SBRT的中位间隔为23个月(范围7-52个月),6例(29%)为中心型肿瘤。
- 再程SBRT后中位随访24个月(范围3-60个月),中位总生存39个月。
- 再程SBRT后2年原发肿瘤控制81%、区域淋巴结控制89%、远地控制75%、总生存68%。
- 2级肺炎2例(10%),2级胸壁毒性4例(19%),未见3级及以上毒性。
关键数值与推荐
- 局部失败定义为距初始PTV 1 cm内或两次治疗≥25%等剂量线重叠。
- 距PTV超过1 cm且无≥25%重叠,或伴其他复发部位者被排除。
- 两程SBRT均为3-5次、BED10≥100 Gy。
临床怎么用
- 对初次肺SBRT后孤立局部复发且符合上述局部失败定义的患者,可考虑再程SBRT作为挽救治疗。
- 再程SBRT需关注2级肺炎和胸壁毒性风险。
局限性
- 样本量小(21例),来自单前瞻性登记数据库。
- 中位随访24个月,随访时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Optimal management of isolated local recurrences after stereotactic body radiation therapy (SBRT) for early non-small cell lung cancer (NSCLC) is unknown and literature describing repeat SBRT for in-field recurrences after initial SBRT are sparse. We investigate the safety and efficacy of salvage SBRT for isolated local failures after initial SBRT for NSCLC. METHODS/MATERIALS: Patients receiving SBRT for isolated local recurrence after initial SBRT for early NSCLC were identified using a prospective registry. Both courses were 3-5 fractions with a biologically effective dose (BED10) of ≥100 Gy. Local failure was defined as within 1 cm of the initial planning target volume (PTV) or an overlap of the ≥25% isodose lines of the first and second treatments. Failures >1 cm beyond the PTV and without ≥25% overlap, or with additional recurrence sites were excluded. Kaplan-Meier analysis was used to estimate survival. RESULTS: A total 21 patients receiving salvage SBRT from 2008 to 2017 were identified. Median interval from initial SBRT to salvage SBRT was 23 months (7-52). Six patients (29%) had central tumors. Median follow-up time from salvage SBRT was 24 months (3-60). Median overall survival after salvage was 39 months. After reirradiation, two-year primary tumor control was 81%, regional nodal control was 89%, distant control was 75% and overall survival was 68%. Grade 2 pneumonitis occurred in 2 patients (10%) and grade 2 chest wall toxicity in 4 patients (19%). No grade 3+ toxicity was observed. CONCLUSIONS: Salvage SBRT for isolated local failures after initial SBRT appears safe, with low treatment-related toxicity and encouraging rates of tumor control.
引用
- Kennedy WR, Gabani P, Nikitas J, et al. Repeat stereotactic body radiation therapy (SBRT) for salvage of isolated local recurrence after definitive lung SBRT. Radiother Oncol. 2019. PMID: 31481272. doi:10.1016/j.radonc.2019.08.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。